- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 12, 2023
Highlights
- EPS (TTM)
- -$0.41
- Total Revenue (TTM)
- $873.00K
- Gross Profit (TTM)
- $873.00K
- EBITDA (TTM)
- -$187.38M
- Year Range
- $16.64 - $96.50
- Target Price
- $109.56
- ROA (TTM)
- -0.91%
- ROE (TTM)
- -0.94%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DNTH Performance Chart
Dianthus Therapeutics Inc. (DNTH) is up 106.2% since the beginning of the year. At $85 per share, DNTH is trading 12.0% below its 52-week high of $97.
Loading charts...
Returns By Period
Dianthus Therapeutics Inc. (DNTH) has returned 106.19% so far this year and 383.06% over the past 12 months.
Dianthus Therapeutics Inc.
- 1D
- 4.17%
- 1M
- -4.89%
- YTD
- 106.19%
- 6M
- 93.25%
- 1Y
- 383.06%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
DNTH Monthly Returns History
Based on dividend-adjusted daily data since Sep 12, 2023, DNTH's average daily return is +0.41%, while the average monthly return is +8.46%. At this rate, an investment would double in approximately 0.7 years.
Historically, 59% of months were positive and 41% were negative. The best month was Jan 2024 with a return of +82.7%, while the worst month was Apr 2024 at -28.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.
On a daily basis, DNTH closed higher 51% of trading days. The best single day was Jan 22, 2024 with a return of +37.2%, while the worst single day was Jan 10, 2024 at -19.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 29.56% | 3.37% | 52.06% | 4.62% | 5.93% | -8.64% | 106.19% | ||||||
| 2025 | 1.61% | -2.48% | -16.02% | 20.45% | -20.41% | 7.13% | 10.95% | 14.03% | 66.95% | -11.11% | 25.73% | -6.30% | 89.04% |
| 2024 | 82.69% | 30.26% | 21.21% | -28.83% | 1.22% | 19.76% | 15.07% | -3.19% | -5.03% | 1.75% | -13.89% | -9.13% | 109.62% |
| 2023 | 24.27% | -12.22% | -6.83% | -6.98% | -5.45% |
Benchmark Metrics
Dianthus Therapeutics Inc. has an annualized alpha of 125.11%, beta of 1.12, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 13, 2023.
- This stock captured 382.25% of S&P 500 Index gains but only 18.97% of its losses - a favorable profile for investors.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 125.11%
- Beta
- 1.12
- R²
- 0.05
- Upside Capture
- 382.25%
- Downside Capture
- 18.97%
Return for Risk
Risk / Return Rank
DNTH ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Dianthus Therapeutics Inc. (DNTH) and compare them to S&P 500 Index.
| DNTH | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.59 | ||
| Sortino ratioReturn per unit of downside risk | +2.42 | ||
| Omega ratioGain probability vs. loss probability | 1.66 | 1.41 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 20.29 | 2.93 | +17.36 |
| Martin ratioReturn relative to average drawdown | 51.72 | 13.52 | +38.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Dianthus Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Dianthus Therapeutics Inc. was 53.48%, occurring on Apr 8, 2025. Recovery took 105 trading sessions.
The current Dianthus Therapeutics Inc. drawdown is 11.27%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -53.48%Apr 2025 | 1y 14d | 5mo 4d | 1y 5moMar 2024 - Sep 2025 |
2023 bear market2023 | -50.77%Dec 2023 | 2mo 17d | 22d | 3mo 9dOct 2023 - Jan 2024 |
2024 bear market2024 | -22.66%Jan 2024 | 8d | 4d | 12dJan 2024 - Jan 2024 |
2026 correction2026 | -19.03%Jan 2026 | 1mo 2d | 7d | 1mo 9dDec 2025 - Jan 2026 |
2025 correction2025 | -16.76%Oct 2025 | 24d | 21d | 1mo 15dSep 2025 - Nov 2025 |
Drawdown Indicators
| DNTH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.48% | -56.78% | +3.30% |
Max Drawdown (1Y)Largest decline over 1 year | -19.03% | -9.10% | -9.93% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -11.27% | -0.74% | -10.53% |
Average DrawdownAverage peak-to-trough decline | -17.93% | -10.72% | -7.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.45% | 1.97% | +5.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Dianthus Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Dianthus Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DNTH relative to other companies in the Biotechnology industry. Currently, DNTH has a P/S ratio of 2,710.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DNTH
Add Dianthus Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DNTH